Por Renan Filho · 2026-10-20**Lead**
A new synthetic opioid described by law enforcement as a “super-drug” — approximately ten times more powerful than fentanyl — has been connected to a rising number of fatal overdoses in at least half a dozen U.S. states, according to preliminary reports from state health departments and the Drug Enforcement Administration (DEA). The substance, part of a class of compounds known as nitazenes, has been detected in toxicology screens of victims in states including Ohio, Pennsylvania, Florida, and California, with officials warning that the drug’s extreme potency makes even microscopic doses potentially lethal.
**Context**
The emergence of this ultra-potent opioid comes amid an already devastating overdose crisis. Fentanyl, a synthetic opioid 50 to 100 times stronger than morphine, has been the primary driver of overdose deaths in the United States for years, claiming tens of thousands of lives annually. The new compound — often referred to in street slang as “ISO” or “nitazene” — belongs to a chemical family first synthesized in the 1950s but never approved for medical use. Unlike fentanyl, which is sometimes diverted from pharmaceutical supply chains, these nitazenes are almost exclusively produced in clandestine laboratories, often in China or Mexico, and shipped via mail or smuggled across borders.
According to the DEA’s National Drug Threat Assessment, nitazene-related deaths have been reported in at least 20 states since 2023, but the latest variant appears to be significantly more potent. Forensic chemists have identified the compound as N-desethyl isotonitazene, a metabolite that can bind to opioid receptors with an affinity roughly ten times that of fentanyl. In practical terms, a dose as small as a few grains of salt can cause respiratory arrest. Emergency responders in several jurisdictions have reported administering multiple doses of naloxone — the opioid reversal agent — without success, as the drug’s strength overwhelms standard protocols.
Local health departments in Cuyahoga County, Ohio, and Philadelphia, Pennsylvania, have issued public health advisories after clusters of overdoses were traced to batches of counterfeit pills and powder sold as oxycodone or heroin. In many cases, victims had no knowledge they were ingesting the super-drug. The Centers for Disease Control and Prevention (CDC) has activated its Enhanced State Opioid Overdose Surveillance system to track the spread, but data collection lags behind the pace of new outbreaks.
**Analise**
The arrival of a drug ten times stronger than fentanyl represents a dangerous escalation in the opioid epidemic. While fentanyl already pushed the boundaries of what the human body can tolerate, this new compound effectively eliminates the margin for error. Users accustomed to fentanyl may inadvertently consume a lethal dose if their dealer switches suppliers or if the drug is mixed unevenly. Moreover, the increased potency complicates harm-reduction strategies: standard test strips designed to detect fentanyl may not react to nitazenes, leaving users blind to the danger. Public health experts warn that the current naloxone distribution model, which typically supplies two-dose kits, may be insufficient. Some emergency medical services are now carrying higher-dose naloxone formulations or multiple kits per call.
From a policy perspective, the rapid emergence of novel synthetic opioids underscores the limitations of scheduling drugs one by one. The DEA has temporarily placed several nitazene compounds under Schedule I control, but chemists can alter molecular structures slightly to create new analogues that are not yet illegal. This cat-and-mouse game has fueled calls for a more flexible regulatory framework, such as a “class-wide” scheduling of all fentanyl-related substances — a proposal that has stalled in Congress amid debates over enforcement and civil liberties. Meanwhile, international cooperation to disrupt precursor chemical shipments remains uneven, with China and India tightening some controls but illicit labs continuing to operate.
**Fontes**
- Drug Enforcement Administration (DEA) National Drug Threat Assessment, 2025. - Centers for Disease Control and Prevention (CDC) Enhanced State Opioid Overdose Surveillance data. - Cuyahoga County Medical Examiner’s Office, Ohio, public health advisory. - Philadelphia Department of Public Health, overdose alert bulletin. - Published reports in the Journal of Analytical Toxicology on nitazene potency. - Statements from the Office of National Drug Control Policy (ONDCP).